First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis

Psoriasis (PsO) is a complex immune-mediated disease that afflicts 100 million people. Omilancor is a locally-acting, small molecule that selectively activates the Lanthionine Synthetase C-like 2 (LANCL2) pathway, resulting in immunoregulatory effects at the intersection of immunity and metabolism....

Descripción completa

Detalles Bibliográficos
Autores principales: Tubau-Juni, Nuria, Hontecillas, Raquel, Leber, Andrew, Maturavongsadit, Panita, Chauhan, Jyoti, Bassaganya-Riera, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494925/
https://www.ncbi.nlm.nih.gov/pubmed/34615968
http://dx.doi.org/10.1038/s41598-021-99349-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494925/
https://www.ncbi.nlm.nih.gov/pubmed/34615968
http://dx.doi.org/10.1038/s41598-021-99349-y

Ejemplares similares